08:19 AM EDT, 10/22/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Wednesday that the independent Data Safety Monitoring Board (DSMB) has raised no safety concerns and recommends that the company's Phase 3 study continue without modifications.

The Phase 3 study, which is being conducted under the FDA's Fast Track designation, is assessing the efficacy of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer.

"Repeated consecutive DSMB positive recommendations further strengthen our confidence in the excellent safety and tolerability profile of the BriaCell regimen," said Dr. William Williams, chief executive officer. "We strongly believe in Bria-IMT's potential to transform cancer care and remain determined to make it a reality for patients with metastatic breast cancer who face urgent medical needs."